On March 9, Zhejiang Jolly Pharmaceutical Co.Ltd(300181) ( Zhejiang Jolly Pharmaceutical Co.Ltd(300181) ) released the performance express for 2021. During the reporting period, the company realized an operating revenue of 1.457 billion yuan, an increase of 33.60% over the same period of the previous year; The net profit attributable to shareholders of listed companies was 179 million yuan, an increase of 101.28% over the same period of last year; Deduct non net profit of 174 million yuan, with a year-on-year increase of 107.16%.
During the reporting period, Zhejiang Jolly Pharmaceutical Co.Ltd(300181) ‘s core products, Wuling capsule, bailing tablet and Lingze tablet, achieved rapid growth in operating revenue. Among them, the operating revenue of Wuling series increased by 40.22% year-on-year and that of Bailing series increased by 24.28% year-on-year.
It is reported that the three core products of Zhejiang Jolly Pharmaceutical Co.Ltd(300181) Wuling capsule, bailing tablet and Lingze tablet have all entered the national catalogue of essential drugs. Last year, the company adhered to the marketing strategy of “stable self operation, strong investment attraction, cloth retail and full module”, and continued to increase market investment and development coverage of terminal medical institutions, Thus, the operating revenue of the company’s three core products has achieved rapid growth. At the same time, the company’s traditional Chinese medicine decoction business has also achieved certain results through market expansion and precipitation.
Zhejiang Jolly Pharmaceutical Co.Ltd(300181) of the above three core products, the exclusive product Wuling capsule has great market influence. Wuling capsule is the first traditional Chinese medicine product proposed in China to treat psychological disorders and improve mood. Since its listing for more than 20 years, it has been widely used in psychiatry, neurology, traditional Chinese medicine, otolaryngology, dermatology, Gastroenterology, cardiology, oncology, endocrinology and other departments to treat patients’ sleep and mood disorders.
At present, Zhejiang Jolly Pharmaceutical Co.Ltd(300181) Wuling capsule has been recommended by 30 clinical guidelines and expert consensus, including expert consensus on the clinical application of Wuling capsule in psychosomatic related disorders, expert guidance on psychosomatic treatment of anxiety and depression under epidemic stress, expert guidance on psychosomatic treatment of mixed anxiety and depression under epidemic stress, It has been successfully selected into the first batch of “Zhejiang famous drugs” in Zhejiang Province.
According to the comprehensive statistical ranking of China’s over-the-counter drug manufacturers and products in 2020, Zhejiang Jolly Pharmaceutical Co.Ltd(300181) Wuling capsule ranked third in the “headache and insomnia category” of China’s over-the-counter drug comprehensive statistical ranking (Chinese patent medicine) in 2020, and the holding subsidiary Everest pharmaceutical bailing tablet ranked ninth in the “tonic category” of China’s over-the-counter drug comprehensive statistical ranking (Chinese patent medicine) in 2020. With the great success of Wuling capsule, now Zhejiang Jolly Pharmaceutical Co.Ltd(300181) has started the secondary development of Wuling capsule to explore its pharmacological efficacy research and high-level evidence-based medicine research in Alzheimer’s disease.
According to the Research Report on market prospects and investment opportunities of China’s biomedical industry from 2020 to 2025 issued by China Commercial Industry Research Institute, the sales revenue of nervous system drugs in China will increase from 144 billion yuan in 2015 to 204.3 billion yuan in 2019, with an annual compound growth rate of 9.1%. It is expected to further increase at an annual compound growth rate of 4.6% from 2020 to 2024, reaching 250.9 billion yuan in 2024.
According to the performance forecast released on the same day, in the first quarter of 2022, Zhejiang Jolly Pharmaceutical Co.Ltd(300181) it is estimated that the net profit attributable to the shareholders of the listed company will be 67-71 million yuan, with a year-on-year increase of 52.98% – 62.12%; The net profit deducted from non profits was 65.9 million yuan to 70.1 million yuan, with a year-on-year increase of 52.25% – 61.95%.
Zhejiang Jolly Pharmaceutical Co.Ltd(300181) said that in the first quarter of this year, the operating revenue of the company’s main products Wuling capsule, bailing tablet and Lingze tablet achieved rapid growth; At the same time, with the improvement of the company’s profitability, the company has more abundant funds, the loan scale has decreased, and the financial expenses have decreased compared with the same period last year.
